Phase 2 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who fully understand the study and are willing to sign a consent form agreeing to take part.
- People aged between 18 and 75 years old, with no restriction on gender.
- People with advanced solid tumour cancers (confirmed by laboratory testing of tissue or cell samples) whose cancer has not responded to standard treatments or who were unable to tolerate standard treatments.
Who may not be able to join:
- People whose medical history, CT scan, or MRI shows that cancer has spread to the brain or central nervous system.
- People who have had another type of cancer within the past 5 years.
- People whom the trial doctor considers unsuitable for the study for any other reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jason Wu, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phone: +86-0512-57018310
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose limited toxicity(DLT); Adverse Event (AE); Maximum tolerated dose(MTD); Recommended phase II dose(RP2D)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.